develop
countermeasur
merscov
infect
rodent
small
anim
model
mimic
human
diseas
hallmark
would
use
initi
screen
studi
measur
test
larger
anim
eg
nonhuman
primat
potenti
camel
although
upper
respiratori
tract
diseas
develop
sever
latter
studi
immun
correl
protect
vaccin
efficaci
camel
natur
host
besid
bat
human
identifi
thu
far
may
reveal
vulner
merscov
may
exploit
human
vaccin
strategi
develop
mer
vaccin
face
sever
challeng
exist
small
anim
speci
natur
express
primari
receptor
merscov
use
infect
human
human
dipeptidylpeptidas
receptor
lack
result
anim
inabl
sustain
infect
clinic
ill
develop
merscov
larger
anim
model
nonhuman
primat
yet
optim
consist
mimic
diseas
pattern
observ
human
infect
incomplet
understood
also
associ
logist
challeng
work
must
complet
biosafeti
level
facil
mous
support
merscov
infect
although
effort
made
adapt
merscov
exhibit
human
diseas
phenotyp
rodent
greater
success
achiev
develop
special
mous
model
express
mous
strain
global
express
suscept
infect
merscov
mice
display
lower
respiratori
tract
infect
weight
loss
increas
respiratori
rate
also
enceph
make
strain
highli
lethal
human
express
howev
transient
limit
lung
transduct
intranas
inocul
infect
transgen
mice
exhibit
transcript
activ
gene
encod
classic
antivir
cytokin
interferon
ifn
proinflammatori
cytokin
interleukin
il
tumor
necrosi
factor
tnf
well
chemokin
granulocytecoloni
stimul
factor
gcsf
monocyt
chemoattract
interferon
gammainduc
protein
cxc
motif
ligand
macrophag
protein
chemokin
cc
motif
ligand
rant
contrast
neglig
gene
activ
infect
nontransgen
mice
gcsf
rant
interferoninduc
gtpbind
protein
detect
lung
brain
infect
transgen
mice
howev
format
hybrid
dimer
transgen
mice
could
affect
immun
regul
lead
poorli
understood
outcom
could
confus
interpret
diseas
natur
histori
vaccin
efficaci
altern
minim
modifi
version
mous
mutat
amino
acid
support
merscov
infect
mice
mutat
experi
sever
lower
respiratori
tract
infect
although
exhibit
brain
infect
addit
pascal
et
al
develop
mice
express
control
endogen
promot
untransl
region
show
lungspecif
infect
inflamm
test
may
prove
vaccin
evalu
small
anim
model
could
lead
better
understand
immunogen
efficaci
vaccin
candid
therapeut
measur
consid
evalu
larger
anim
human
among
current
nonhuman
primat
model
rhesu
macaqu
display
mildtomoder
clinic
sign
viral
challeng
wherea
common
marmoset
report
exhibit
sever
sign
infect
could
better
model
sever
clinic
syndrom
observ
person
howev
research
group
abl
replic
sever
diseas
outcom
marmoset
factor
contribut
could
includ
variat
physic
locat
age
origin
marmoset
challeng
viru
strain
stock
rout
dose
inocul
protocol
abl
provid
robust
reproduc
outcom
nonhuman
primat
model
need
addit
develop
optim
standard
camel
also
use
evalu
merscov
infect
find
adney
et
al
show
anim
uniqu
experi
upper
respiratori
tract
infect
although
know
effici
airborn
versu
droplet
anoth
mode
transmiss
viral
shed
upper
respiratori
tract
might
explain
effici
transmiss
although
camel
display
sever
diseas
symptom
observ
infect
human
camel
infect
model
remain
use
understand
diseas
camel
identifi
potenti
immun
correl
protect
induc
vaccin
veterinari
countermeasur
could
form
part
one
health
strategi
forestal
zoonot
transmiss
human
hesit
implement
anim
vaccin
strategi
camel
vaccin
becom
avail
attribut
absenc
sever
diseas
camel
upper
respiratori
tract
infect
rhiniti
skeptic
among
key
group
regard
zoonot
transmiss
merscov
human
eg
camel
breeder
although
anim
model
evalu
merscov
infect
repres
progress
recapitul
pathogenesi
sever
human
diseas
combin
small
larg
anim
model
consid
evalu
prevent
therapeut
candid
mer
regardless
chosen
model
compar
interpret
result
effect
reduc
discrep
among
laboratori
crucial
research
agre
set
standard
respect
experiment
design
includ
variabl
age
anim
specimen
handl
rout
administr
type
viru
challeng
inocul
schedul
sampl
collect
diseas
score
algorithm
build
experi
close
relat
sever
acut
respiratori
syndrom
coronaviru
sarscov
research
activ
work
understand
merscov
genet
inform
vaccin
therapeut
develop
effort
quickli
demonstr
spike
protein
viral
surfac
glycoprotein
essenti
recognit
viral
entri
cell
like
repres
prime
target
immunogen
design
develop
vaccin
monoclon
antibodi
workshop
review
variou
preclin
develop
base
protein
one
compon
includ
nanoparticl
subunit
protein
peptid
dna
variou
viral
vector
live
attenu
merscov
nanoparticl
form
merscov
protein
develop
novavax
gaithersburg
maryland
usa
shown
induc
viru
neutral
antibodi
nab
mice
singl
inject
proprietari
adjuv
enhanc
respons
vaccin
use
antigen
express
baculoviru
platform
develop
novavax
evalu
human
subject
context
phase
phase
ii
clinic
studi
infecti
diseas
without
notabl
vaccinerel
safeti
concern
portion
protein
specif
receptorbind
domain
also
develop
subunit
vaccin
jiang
note
fragment
map
critic
neutral
region
induc
strong
immun
respons
nab
mous
model
moreov
subunit
vaccin
shown
protect
transgen
mice
challeng
merscov
indic
vaccin
focus
receptorbind
domain
may
suffici
protect
immun
develop
viru
sever
viral
vector
includ
adenoviru
modifi
vaccinia
ankara
mva
measl
viru
also
develop
differ
group
variou
length
protein
express
platform
abl
gener
antibodi
anim
neutral
merscov
vitro
least
vector
platform
also
gener
cellular
immun
respons
mva
measl
vaccin
respons
confer
protect
mice
mva
construct
establish
safeti
profil
human
test
camel
induc
protect
immun
repres
potenti
veterinari
technolog
moreov
basi
support
data
anim
studi
mva
construct
soon
enter
clinic
trial
vaccin
base
live
attenu
virus
histor
shown
highli
efficaci
also
safe
gener
well
toler
enjuan
other
report
group
develop
engin
merscov
vaccin
candid
one
candid
base
propagationdefect
merscov
strain
anoth
live
attenu
viru
safeti
guard
use
merscov
infecti
cdna
clone
inactiv
sarscov
vaccin
shown
safe
abl
induc
nab
phase
trial
dna
vaccin
gener
perceiv
safe
stabl
platform
vivo
antigen
express
sarscov
dna
vaccin
express
sarscov
protein
shown
induc
nab
function
tcell
respons
human
geneon
blue
bell
pa
usa
develop
proprietari
fulllength
protein
dna
vaccin
candid
shown
induc
nab
highli
function
cell
variou
anim
model
protect
rhesu
macaqu
infect
merscov
challeng
vaccin
administ
electropor
enhanc
uptak
plasmid
dna
concern
remain
regard
immunogen
dna
vaccin
human
although
effect
use
therapeut
vaccin
strategi
diseas
rais
potenti
dnaonli
approach
addit
modjarrad
report
use
primeboost
format
fulllength
protein
dna
vaccin
follow
sprotein
boost
increas
nab
titer
reduc
clinic
sever
mer
increas
durabl
protect
macaqu
complement
activ
immun
approach
research
also
advanc
sever
prophylact
therapeut
approach
merscov
use
nab
technolog
preclin
develop
nab
target
epitop
protein
specif
receptorbind
domain
caus
precis
potent
inhibitori
effect
viral
entri
small
larg
anim
model
mechan
neutral
uncov
typic
mediat
block
merscov
bind
supplementari
agent
antibodi
peptid
merscov
fusion
inhibitor
target
conserv
region
protein
domain
region
highli
potent
inhibit
infect
merscov
strain
includ
resist
nab
intranas
administr
peptid
protect
mice
merscov
challeng
suggest
alon
combin
nab
peptid
could
use
prevent
treat
merscov
infect
character
technolog
potenti
combin
approach
ongo
investig
tackl
question
relat
viral
escap
preliminari
result
indic
virus
evad
antibodi
neutral
reduc
viral
fit
demonstr
escap
occur
come
cost
fit
nevertheless
continu
investig
surveil
warrant
marasco
note
sequenc
circul
strain
critic
monitor
viral
evolut
possibl
increas
sampl
datashar
ongo
studi
relat
crossreact
human
tissu
effect
polyclon
nonneutr
antibodi
also
underway
passiv
immunotherapi
becom
accept
prevent
treat
merscov
infect
overal
select
specif
technolog
approach
warrant
develop
difficult
given
divers
model
readout
concomit
need
greater
standard
field
although
technolog
present
uniqu
advantag
defici
relat
desir
immunogen
safeti
durabl
protect
need
adjuv
manufactur
consider
technolog
long
track
record
clinic
would
potenti
simplifi
develop
regulatori
pathway
given
public
health
urgenc
platform
combin
thereof
made
prioriti
experi
sarscov
offer
sober
lesson
countermeasur
advanc
basi
promis
preclin
data
may
ultim
exacerb
diseas
human
antibodydepend
enhanc
infect
observ
cell
cultur
human
promonocyt
cell
line
use
mice
hamster
vaccin
recombin
nativ
fulllength
sarscov
protein
trimer
serum
igg
develop
block
bind
protein
receptor
neutral
sarscov
infect
vitro
sarscov
enter
human
bcell
line
fashion
indic
antibodydepend
enhanc
viru
entri
novel
cell
entri
mechan
sarscov
vaccin
anim
show
sign
enhanc
lung
patholog
hepat
viral
load
undetect
greatli
reduc
lung
challeng
sarscov
howev
presenc
absenc
adjuv
vaccin
mice
viruslik
particl
inactiv
viru
induc
eosinophil
immunopatholog
chang
young
age
mice
pulmonari
immunopatholog
featur
challeng
sarscov
associ
immunopatholog
promin
eosinophil
infiltr
although
enhanc
immunopatholog
featur
observ
anim
futur
studi
merscov
vaccin
anim
human
consid
possibl
date
commit
open
commun
regard
merscov
vaccin
develop
haphazard
leader
field
call
new
approach
integr
resourc
acceler
scienc
enhanc
biosecur
new
norm
standard
develop
world
health
organ
streamlin
sampl
collect
type
storag
avail
qualiti
control
inform
dissemin
public
combin
resourc
avail
saudi
arabia
south
korea
unit
state
europ
beyond
develop
countermeasur
merscov
open
innov
paradigm
shift
maxim
public
sector
invest
provid
robust
inform
systemslevel
approach
deliv
necessari
public
health
effect
urgent
need
saudi
arabia
moh
work
saudi
academ
institut
stakehold
recogn
crucial
role
play
defin
public
health
goal
guid
vaccin
develop
effort
merscov
research
vaccin
develop
health
author
must
understand
vaccin
expect
fit
larger
public
health
strategi
combat
mer
eg
target
popul
vaccin
strategi
level
efficaci
safeti
profil
vaccin
well
pathway
futur
vaccin
test
eg
design
efficaci
trial
licensur
access
vaccin
develop
mer
arena
experi
conduct
preclin
clinic
research
middl
east
saudi
moh
saudi
food
drug
author
valuabl
role
play
defin
expect
futur
clinic
studi
educ
develop
associ
regulatori
pathway
potenti
threat
pose
merscov
necessit
multiprong
approach
develop
effect
countermeasur
salient
public
health
messag
workshop
includ
follow
point
acceler
develop
vaccin
requir
better
understand
merscov
epidemiolog
transmiss
pathogenesi
human
anim
inform
help
develop
target
product
profil
human
veterinari
vaccin
turn
facilit
plan
efficaci
trial
inform
develop
strategi
current
anim
model
fulli
reflect
hallmark
sever
human
diseas
combin
rodent
nonhuman
primat
model
consid
evalu
develop
prevent
therapeut
candid
standard
condit
current
vaccin
develop
strategi
involv
varieti
technolog
platform
primarili
target
merscov
protein
given
public
health
urgenc
platform
combin
thereof
establish
safeti
track
record
human
given
prioriti
target
speci
dromedari
camel
also
consid
develop
veterinari
vaccin
one
health
approach
attent
paid
lesson
learn
sarscov
vaccin
develop
effort
particularli
sign
potenti
diseas
enhanc
variou
anim
model
therapeut
antibodi
recogn
potenti
use
tool
mer
prevent
treatment
concern
around
escap
mutant
increas
fit
although
concern
limit
technolog
type
warrant
continu
investig
surveil
approach
could
consid
alon
combin
vaccin
approach
supplementari
agent
peptid
fusion
inhibitor
may
develop
mer
prophylact
therapeut
opportun
exist
greater
coordin
around
specif
technolog
platform
ensur
appropri
incent
consid
stimul
research
develop
collabor
academia
industri
nongovernment
organ
govern
saudi
arabia
moh
work
stakehold
crucial
role
play
defin
public
health
goal
guid
vaccin
develop
effort
fund
agenc
nongovernment
organ
compani
recogn
need
cooper
resolv
formal
collabor
model
field
recogn
opportun
set
preced
collabor
global
commun
context
emerg
diseas
build
lesson
learn
recent
intern
respons
ebola
epidem
although
still
subject
consult
key
compon
partnership
identifi
includ
coordin
fund
share
samplesdata
advanc
preclin
model
begin
clinic
trial
region
outbreak
standard
assay
reagent
test
exact
partnership
structur
remain
determin
least
allow
coordin
activ
frequent
transpar
open
discuss
among
fund
agenc
stakehold
futur
model
includ
formal
consortium
player
would
make
longterm
commit
advanc
select
product
develop
phase
contempl
technolog
evalu
rigor
regardless
final
partnership
structur
core
collabor
strategi
includ
share
data
sampl
standard
laboratori
assay
ensur
everyon
learn
abl
compar
technolog
ultim
acceler
develop
new
solut
